Home > > > Report Detail

(Post-pandemic Era) - Global Alpha-1 Lung Disease Market Segment Research Report 2022

Publisher Name :
Date: 13-May-2022
No. of pages: 113

Summary

The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.

2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.

According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.

Beijing Yanjing Bizhi Information Consulting Co., Ltd. (XYZResearch) released the «Global Alpha-1 Lung Disease Market Segment Research Report 2022», which aims to sort out the development status and trends of the Alpha-1 Lung Disease industry at home and abroad, estimate the overall market scale of the Alpha-1 Lung Disease industry and the market share of major countries, analyze the development potential of each segment of the Alpha-1 Lung Disease industry, and study and judge the downstream market demand of Alpha-1 Lung Disease through systematic research, Analyze the competition pattern of Alpha-1 Lung Disease, so as to help solve the pain points of various stakeholders in Alpha-1 Lung Disease industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.

Regional Segmentation (Value; Revenue, USD Million, 2017 - 2027) of Alpha-1 Lung Disease Market by XYZResearch Include

- USA

- Europe

- China

- Japan

- India

- Korea

- Southeast Asia

Competitive Analysis; Who are the Major Players in Alpha-1 Lung Disease Market?

- Pfizer

- Baxter

- AstraZeneca

- Grifols

- Teva Pharmaceutical Industries

- Boehringer Ingelheim

- Kamada Ltd

- GlaxoSmithKline

- CSL Behring

- Takeda

- LFB Biomedicaments

- Abeona Therapeutics

- Biogen

- Vertex Pharmaceuticals

- Baxalta

- Arrowhead Research Corporation

- ProBioGen

- Chiesi Pharmaceuticals

- Kedrion Group

- ProMetic Life Sciences

Major Type of Alpha-1 Lung Disease Covered in XYZResearch report:

- Augmentation Therapy

- Cystic Fibrosis(CF)

- Non-CF Bronchiectasis(NCFB)

- Other

Application Segments Covered in XYZResearch Market

- Hospitals

- Specialty Clinics

- Pharmacies

- Others

For any other requirements, please feel free to contact us and we will provide you customized report.

(Post-pandemic Era) - Global Alpha-1 Lung Disease Market Segment Research Report 2022

Table of Contents

Global Alpha-1 Lung Disease Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Alpha-1 Lung Disease Market by Value
2.2.1 Global Alpha-1 Lung Disease Revenue by Type
2.2.2 Global Alpha-1 Lung Disease Market by Value (%)
2.3 Global Alpha-1 Lung Disease Market by Production
2.3.1 Global Alpha-1 Lung Disease Production by Type
2.3.2 Global Alpha-1 Lung Disease Market by Production (%)

3. The Major Driver of Alpha-1 Lung Disease Industry
3.1 Historical & Forecast Global Alpha-1 Lung Disease Demand
3.2 Largest Application for Alpha-1 Lung Disease (2018-2028)
3.3 The Major Downstream Company in China Market 2022

4. Global and Regional Alpha-1 Lung Disease Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2019-2027)
4.3 Concentration Ratio (CR5& CR10) of Alpha-1 Lung Disease Market
4.4 Mergers & Acquisitions, Expansion Plans

5. US Alpha-1 Lung Disease Production, Demand (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Demand Breakdown by Type
5.3 Current and Estimated Demand Breakdown by Application
5.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

6. Europe Alpha-1 Lung Disease Production, Demand (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Demand Breakdown by Type
6.3 Current and Estimated Demand Breakdown by Application
6.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

7. China Alpha-1 Lung Disease Production, Demand (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Demand Breakdown by Type
7.3 Current and Estimated Demand Breakdown by Application
7.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

8. Japan Alpha-1 Lung Disease Production, Demand (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Demand Breakdown by Type
8.3 Current and Estimated Demand Breakdown by Application
8.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

9. India Alpha-1 Lung Disease Production, Demand (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Demand Breakdown by Type
9.3 Current and Estimated Demand Breakdown by Application
9.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

10. Korea Alpha-1 Lung Disease Production, Demand (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Demand Breakdown by Type
10.3 Current and Estimated Demand Breakdown by Application
10.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

11. Southeast Asia Alpha-1 Lung Disease Production, Demand (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Demand Breakdown by Type
11.3 Current and Estimated Demand Breakdown by Application
11.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

12. Global Alpha-1 Lung Disease Average Price Trend
12.1 Market Price for Each Type of Alpha-1 Lung Disease in US (2018-2022)
12.2 Market Price for Each Type of Alpha-1 Lung Disease in Europe (2018-2022)
12.3 Market Price for Each Type of Alpha-1 Lung Disease in China (2018-2022)
12.4 Market Price for Each Type of Alpha-1 Lung Disease in Japan (2018-2022)
12.5 Market Price for Each Type of Alpha-1 Lung Disease in India (2018-2022)
12.6 Market Price for Each Type of Alpha-1 Lung Disease in Korea (2018-2022)
12.7 Market Price for Each Type of Alpha-1 Lung Disease in Southeast Asia (2018-2022)

13. Industrial Chain (Impact of COVID-19)
13.1 Alpha-1 Lung Disease Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Technology Trends of Alpha-1 Lung Disease

14. Alpha-1 Lung Disease Competitive Landscape
14.1 Pfizer
14.1.1 Pfizer Company Profiles
14.1.2 Pfizer Product Introduction
14.1.3 Pfizer Alpha-1 Lung Disease Sales, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 Baxter
14.2.1 Baxter Company Profiles
14.2.2 Baxter Product Introduction
14.2.3 Baxter Alpha-1 Lung Disease Sales, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 AstraZeneca
14.3.1 AstraZeneca Company Profiles
14.3.2 AstraZeneca Product Introduction
14.3.3 AstraZeneca Alpha-1 Lung Disease Sales, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 Grifols
14.4.1 Grifols Company Profiles
14.4.2 Grifols Product Introduction
14.4.3 Grifols Alpha-1 Lung Disease Sales, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 Teva Pharmaceutical Industries
14.5.1 Teva Pharmaceutical Industries Company Profiles
14.5.2 Teva Pharmaceutical Industries Product Introduction
14.5.3 Teva Pharmaceutical Industries Alpha-1 Lung Disease Sales, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 Boehringer Ingelheim
14.6.1 Boehringer Ingelheim Company Profiles
14.6.2 Boehringer Ingelheim Product Introduction
14.6.3 Boehringer Ingelheim Alpha-1 Lung Disease Sales, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 Kamada Ltd
14.7.1 Kamada Ltd Company Profiles
14.7.2 Kamada Ltd Product Introduction
14.7.3 Kamada Ltd Alpha-1 Lung Disease Sales, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 GlaxoSmithKline
14.8.1 GlaxoSmithKline Company Profiles
14.8.2 GlaxoSmithKline Product Introduction
14.8.3 GlaxoSmithKline Alpha-1 Lung Disease Sales, Revenue (2018-2022)
14.8.4 Strategic initiatives
14.9 CSL Behring
14.9.1 CSL Behring Company Profiles
14.9.2 CSL Behring Product Introduction
14.9.3 CSL Behring Alpha-1 Lung Disease Sales, Revenue (2018-2022)
14.9.4 Strategic initiatives
14.10 Takeda
14.10.1 Takeda Company Profiles
14.10.2 Takeda Product Introduction
14.10.3 Takeda Alpha-1 Lung Disease Sales, Revenue (2018-2022)
14.10.4 Strategic initiatives
14.11 LFB Biomedicaments
14.12 Abeona Therapeutics
14.13 Biogen
14.14 Vertex Pharmaceuticals
14.15 Baxalta
14.16 Arrowhead Research Corporation
14.17 ProBioGen
14.18 Chiesi Pharmaceuticals
14.19 Kedrion Group
14.20 ProMetic Life Sciences
15. Conclusion

List of Tables and Figures

Figure 1. Total Demand by Application of Alpha-1 Lung Disease Industry (Volume)
Figure 2. Alpha-1 Lung Disease Production & Demand by Regions in 2021
Figure 3. Regional Market Share in Terms of Revenue (2021&2027)
Figure 4. The Top 10 and 5 Players Market Share by Alpha-1 Lung Disease Revenue in 2021
Figure 5. US Alpha-1 Lung Disease Production, Demand (2018-2028)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Alpha-1 Lung Disease Production, Demand (2018-2028)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Alpha-1 Lung Disease Production, Demand (2018-2028)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Alpha-1 Lung Disease Production, Demand (2018-2028)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Alpha-1 Lung Disease Production, Demand (2018-2028)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Alpha-1 Lung Disease Production, Demand (2018-2028)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Alpha-1 Lung Disease Production, Demand (2018-2028)
Figure 43. Current and Estimated Production Breakdown by Type (2018-2028)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Alpha-1 Lung Disease Revenue, by Type (Million USD) (2018-2028)
Table 4. Alpha-1 Lung Disease Production, by Type (K Unit) (2018-2028)
Table 5. Alpha-1 Lung Disease Demand (K Unit) by Application (2018-2028)
Table 6. Alpha-1 Lung Disease Demand (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2021)
Table 9. Regional Market Share in Terms of Revenue (2021&2027)
Table 10. Ranking of Global Top Alpha-1 Lung Disease Companies by Revenue, Concentration Ratio in 2021
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Alpha-1 Lung Disease Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 13. Current and Estimated Production Breakdown by Type (2018-2028)
Table 14. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 15. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Alpha-1 Lung Disease Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 19. Current and Estimated Production Breakdown by Type (2018-2028)
Table 20. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 21. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Alpha-1 Lung Disease Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Alpha-1 Lung Disease Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 30. Current and Estimated Production Breakdown by Type (2018-2028)
Table 31. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 32. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Alpha-1 Lung Disease Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 36. Current and Estimated Production Breakdown by Type (2018-2028)
Table 37. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 38. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Alpha-1 Lung Disease Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 42. Current and Estimated Production Breakdown by Type (2018-2028)
Table 43. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 44. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Alpha-1 Lung Disease Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 48. Table Current and Estimated Demand Breakdown by Type (2018-2028)
Table 49. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Alpha-1 Lung Disease in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Alpha-1 Lung Disease in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Alpha-1 Lung Disease in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Alpha-1 Lung Disease in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Alpha-1 Lung Disease in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Alpha-1 Lung Disease in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Alpha-1 Lung Disease in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Pfizer Profiles
Table 61. Pfizer Alpha-1 Lung Disease Product Introduction
Table 62. Pfizer Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Pfizer Strategic initiatives
Table 64. Baxter Profiles
Table 65. Baxter Alpha-1 Lung Disease Product Introduction
Table 66. Baxter Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. Baxter Strategic initiatives
Table 68. AstraZeneca Profiles
Table 69. AstraZeneca Alpha-1 Lung Disease Product Introduction
Table 70. AstraZeneca Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. AstraZeneca Strategic initiatives
Table 72. Grifols Profiles
Table 73. Grifols Alpha-1 Lung Disease Product Introduction
Table 74. Grifols Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Grifols Strategic initiatives
Table 76. Teva Pharmaceutical Industries Profiles
Table 77. Teva Pharmaceutical Industries Alpha-1 Lung Disease Product Introduction
Table 78. Teva Pharmaceutical Industries Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Teva Pharmaceutical Industries Strategic initiatives
Table 80. Boehringer Ingelheim Profiles
Table 81. Boehringer Ingelheim Alpha-1 Lung Disease Product Introduction
Table 82. Boehringer Ingelheim Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. Boehringer Ingelheim Strategic initiatives
Table 84. Kamada Ltd Profiles
Table 85. Kamada Ltd Alpha-1 Lung Disease Product Introduction
Table 86. Kamada Ltd Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Kamada Ltd Strategic initiatives
Table 88. GlaxoSmithKline Profiles
Table 89. GlaxoSmithKline Alpha-1 Lung Disease Product Introduction
Table 90. GlaxoSmithKline Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. GlaxoSmithKline Strategic initiatives
Table 92. CSL Behring Profiles
Table 93. CSL Behring Alpha-1 Lung Disease Product Introduction
Table 94. CSL Behring Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. CSL Behring Strategic initiatives
Table 97. Takeda Profiles
Table 98. Takeda Alpha-1 Lung Disease Product Introduction
Table 99. Takeda Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. Takeda Strategic initiatives
Table 101. LFB Biomedicaments Profiles
Table 102. LFB Biomedicaments Alpha-1 Lung Disease Product Introduction
Table 103. LFB Biomedicaments Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 104. LFB Biomedicaments Strategic initiatives
Table 105. Abeona Therapeutics Profiles
Table 106. Abeona Therapeutics Alpha-1 Lung Disease Product Introduction
Table 107. Abeona Therapeutics Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 108. Abeona Therapeutics Strategic initiatives
Table 109. Biogen Profiles
Table 110. Biogen Alpha-1 Lung Disease Product Introduction
Table 111. Biogen Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 112. Biogen Strategic initiatives
Table 113. Vertex Pharmaceuticals Profiles
Table 114. Vertex Pharmaceuticals Alpha-1 Lung Disease Product Introduction
Table 115. Vertex Pharmaceuticals Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 116. Vertex Pharmaceuticals Strategic initiatives
Table 117. Baxalta Profiles
Table 118. Baxalta Alpha-1 Lung Disease Product Introduction
Table 119. Baxalta Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 120. Baxalta Strategic initiatives
Table 121. Arrowhead Research Corporation Profiles
Table 122. Arrowhead Research Corporation Alpha-1 Lung Disease Product Introduction
Table 123. Arrowhead Research Corporation Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 124. Arrowhead Research Corporation Strategic initiatives
Table 125. ProBioGen Profiles
Table 126. ProBioGen Alpha-1 Lung Disease Product Introduction
Table 127. ProBioGen Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 128. ProBioGen Strategic initiatives
Table 129. Chiesi Pharmaceuticals Profiles
Table 130. Chiesi Pharmaceuticals Alpha-1 Lung Disease Product Introduction
Table 131. Chiesi Pharmaceuticals Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 132. Chiesi Pharmaceuticals Strategic initiatives
Table 133. Kedrion Group Profiles
Table 134. Kedrion Group Alpha-1 Lung Disease Product Introduction
Table 135. Kedrion Group Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
Table 136. Kedrion Group Strategic initiatives
Table 137. ProMetic Life Sciences Profiles
Table 138. ProMetic Life Sciences Alpha-1 Lung Disease Product Introduction
Table 139. ProMetic Life Sciences Alpha-1 Lung Disease Sales (Unit), Revenue (Million USD) (2018-2022)
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs